BETA3_LVH | A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease
01-05-2015
-31-08-2022
Show more information
Organisation
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES